tradingkey.logo

Moderna rises after Q4 revenue beat

ReutersFeb 13, 2026 2:22 PM

Shares of vaccine maker Moderna MRNA.O rise 2.6% to $41.11 premarket

Co posts Q4 revenue of $678 million, beating LSEG-compiled analysts' average expectation of $626.1 million

Sales were primarily driven by Moderna's COVID-19 vaccine franchise

Reports a narrower quarterly loss of $2.11 per share from last year's loss of $2.91 per share

Up to last close, stock rose 36% YTD; MRNA fell 29% in 2025

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI